서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 32 of 32

Issue DateTitle / Author(s) / CitationFileAltmetrics
2008-04
Resveratrol induces the suppression of tumor-driven CD4(+) CD25(+) regulatory T cells

Yang, Yoolhee; Paik, Jin Ho; Cho, Daeho; Cho, Jung-Ah; Kim, Chul-Woo

International Immunopharmacology, Vol.8 No.4, pp.542-547

DOI
2011-08
Prognostic Significance of HLA Class I Expressing in Gastric Carcinoma Defined by Monoclonal Anti-Pan HLA Class I Antibody, EMR8-5

Lee, Hae-Wan; Min, Soo Kee; Ju, Young-Su; Sung, Joohon; Lim, Man Sup; Yang, Dae Hyun; Lee, Bong Hwa

Journal of Gastrointestinal Surgery, Vol.15 No.8, pp.1336-1343

DOI
2011-08
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
DOI
2012-03
Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients
DOI
2017-04
Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy
DOI
2017-11
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study
DOI
2018-05
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
DOI
2018-11
Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib

Lee, Ji Su; Huh, Chang-Hun; Kwon, Ohsang; Yoon, Hyun-Sun; Cho, Soyun; Park, Hyun-sun

Journal of Dermatological Treatment, Vol.29 No.8, pp.819-822

DOI
2019
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
DOI
2019-03
GM-CSF promotes antitumor immunity by inducing Th9 cell responses
DOI
2019-04
Dynamics of soluble programmed death-ligand 1 (SPDL1) during chemotherapy and its prognostic implications in cancer patients: Biomarker development in immuno-oncology

Ha, Hyerim; Bang, Ju-Hee; Nam, Ah-Rong; Park, Ji-Eun; Jin, Mei Hua; Bang, Yung-Jue; Oh, Do-Youn

Cancer Research and Treatment, Vol.51 No.2, pp.832-840

DOI
2019-04
Recyclable Cytokines on Short and Injectable Polylactic Acid Fibers for Enhancing T-Cell Function
DOI
2019-07
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
DOI
2020-01
Feasibility of real-time in vivo Zr-89-DFO-labeled CAR T-cell trafficking using PET imaging
DOI
2020-03
Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
DOI
2020-06
Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
DOI
2020-10
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
DOI
2021-03
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
DOI
2021-04
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
DOI
2021-06
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
DOI
2021-07
Theragnostic Glycol Chitosan-Conjugated Gold Nanoparticles for Photoacoustic Imaging of Regional Lymph Nodes and Delivering Tumor Antigen to Lymph Nodes
DOI
2021-08
Sustained Responses of Neutralizing Antibodies Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Recovered Patients and Their Therapeutic Applicability
DOI
2021-11
Genome-Editing-Mediated Restructuring of Tumor Immune Microenvironment for Prevention of Metastasis

Kim, Dongyoon; Wu, Yina; Shim, Gayong; Oh, Yu-Kyoung

ACS Nano, Vol.15 No.11, pp.17635-17656

DOI
2022-03
Nanovesicle-Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects
DOI
2022-10
Effects of extracellular adhesion molecules on immune cell mediated solid tumor cell killing

Kim, Seong-Eun; Yun, Suji; Doh, Junsang

Frontiers in Immunology, Vol.13, p. 1004171

DOI
2023-01
A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets
DOI
2023-03
Senescent cancer cell-derived nanovesicle as a personalized therapeutic cancer vaccine
DOI
2023-05
PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion
DOI
2023-09
A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses
DOI
2023-11
The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer
DOI
2024-02
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
DOI
2024-04
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study
DOI
1